19 jul: USA/tendens: Stigninger og masser af regnskaber
19 jul: USA/åbning: Regnskaber belønnes på Wall Street
19-07-2012 15:18:00

Array BioPharma Reaches $8.5 Million Milestone in Amgen Diabetes Agreement

Relateret indhold

By Saabira Chaudhuri

Array BioPharma Inc. (ARRY) has reached a $8.5 million milestone in its agreement with Amgen Inc. (AMGN) to develop a drug to treat diabetes.

Array--a biopharmaceutical company focused on developing small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases--entered the agreement, which is for worldwide development of small-molecule glucokinase activators, including a drug called AMG 151, with Amgen in December 2009.

Under the terms, Amgen paid an up front fee of $60 million. Array is entitled to receive up to about $658 million in additional aggregate milestone payments if all clinical and commercialization milestones specified in the agreement for AMG 151 and at least one backup compound are achieved. Array will also receive royalties on sales of any approved drugs developed under the agreement.

Glucokinase is the enzyme that acts as a glucose sensor in the pancreas and liver. The activation of glucokinase lowers glucose levels by enhancing the ability of the pancreas to sense glucose, which leads to increased insulin production. It also increases the update of blood glucose by the liver.

On Thursday, Array said AMG 151 has previously been found effective in controlling blood glucose. It said the milestone was achieved after Amgen reached a pre-defined patient enrollment level in a Phase 2 clinical trial.

In April, Array said its loss for the fiscal third quarter had narrowed on higher revenue coupled with lower operating expenses.

Shares were up 2.76% in recent premarket trading to $4.10. The stock is up 61% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 19, 2012 09:18 ET (13:18 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Novo: Ny fusion styrker købersiden ved forhandlingsbordet

22-05-2015 14:15:45
Medicinalselskaberne kan formentlig se frem til endnu sværere prisforhandlinger fremover i USA. Modparterne ved forhandlingsbordet, de såkaldte Pharma Benefit M..

Aktier/åbning: Zealand i rødt efter regnskab

22-05-2015 09:18:44
Det danske C20 Cap-indekset starter med bevægelser fra side til side i niveauet 1.016 fredag morgen på en dag, hvor Zealand Pharma - uden for eliteindekset - er..

Novo: Ingeniørmangel vækker flyttetanker - avis

22-05-2015 06:57:32
Danmarks største medicinalkoncern, Novo Nordisk, står lige nu med 100 ledige ingeniørstillinger, som ikke kan besættes. Og ifølge en ny fremskrivning foretaget ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas-kunde forudser vanvittig periode forude
2
MHI Vestas/dir: Succes er kommet langt hurtigere end ventet
3
Novo: Ingeniørmangel vækker flyttetanker - avis
4
Mærsk nær milliardsalg af Esbjerg-rederi - avis
5
Aktier/åbning: Zealand i rødt efter regnskab

Relaterede aktiekurser

Amgen Inc 163,84 0,0% Aktiekurs uændret
Array BioPharma Inc 7,38 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. maj 2015 15:03:06
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150519.1 - EUROWEB3 - 2015-05-22 15:03:06 - 2015-05-22 15:03:06 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x